<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03789916</url>
  </required_header>
  <id_info>
    <org_study_id>72.18</org_study_id>
    <nct_id>NCT03789916</nct_id>
  </id_info>
  <brief_title>SAPT Versus DAPT in Incomplete Revascularization After CABG</brief_title>
  <acronym>SDAT-IRC</acronym>
  <official_title>Single Versus Dual Antiplatelet Therapy in Patients With Incomplete Revascularization After Coronary Artery Bypass Graft Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Campus Bio-Medico University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Campus Bio-Medico University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study aims to compare the efficacy of dual antiplatelet therapy (DAPT) over single
      antiplatelet therapy (SAPT) in patients with incomplete revascularization after coronary
      artery bypass graft surgery (CABG).

      Before hospital discharge, patients will be 1:1 randomized to SAPT (acetylsalicylic acid 100
      mg/die) or DAPT (acetylsalicylic acid 100 mg/die + ticagrelor 90 mg bis in die). DAPT will be
      continued for 12 months, and ticagrelor will be withdrawn thereafter. Primary endpoint is the
      evaluation of cardiac-related mortality at 5 years from hospital discharge.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 2, 2019</start_date>
  <completion_date type="Anticipated">December 31, 2026</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cardiac-related mortality</measure>
    <time_frame>5 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mortality</measure>
    <time_frame>5 years</time_frame>
    <description>Overall mortality and non-cardiac-related mortality</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Major adverse cardiac and cerebrovascular events (MACCEs)</measure>
    <time_frame>5 years</time_frame>
    <description>cardiac-related mortality, myocardial infarction, repeated vessel revascularization, hospitalization for heart failure, major arrhythmias, stroke</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Major adverse hemorrhagic events (MAHEs)</measure>
    <time_frame>5 years</time_frame>
    <description>stroke, gastrointestinal bleeding, life-threatening bleeding</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">800</enrollment>
  <condition>Coronary Artery Disease</condition>
  <arm_group>
    <arm_group_label>DAPT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>&quot;Dual antiplatelet therapy&quot;: acetylsalicylic acid 100 mg/die + ticagrelor 90 mg bis in die</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SAPT</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>&quot;Single antiplatelet therapy&quot;: acetylsalicylic acid 100 mg/die</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ticagrelor</intervention_name>
    <description>90 mg bis in die</description>
    <arm_group_label>DAPT</arm_group_label>
    <other_name>Brilique</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>acetylsalicylic acid</intervention_name>
    <description>100 mg die</description>
    <arm_group_label>DAPT</arm_group_label>
    <arm_group_label>SAPT</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  patients undergoing CABG, ± cardiopulmonary bypass, ± any associated cardiac
             procedures (valve replacement,...)

          -  incomplete myocardial revascularization, defined by anatomic or functional criteria

          -  obtained informed consent

        Exclusion Criteria:

          -  acute coronary syndrome &lt; 12 months from surgery

          -  dual antiplatelet therapy at hospital admission

          -  planned procedure to complete myocardial revascularization (e.g. hybrid approach)

          -  intolerance / unable to take acetylsalicylic acid or ticagrelor

          -  preoperative atrial fibrillation

          -  impaired compliance

          -  planned pregnancy

          -  history of gastrointestinal bleeding

          -  chronic kidney disease (eGFR &lt; 30 mL/min/1.73 m2)

          -  chronic liver disease

          -  severe heart failure at hospital admission

          -  active malignancy

          -  alcohol abuse

          -  any clinical condition not compatible with the treatment

        Exit Criteria:

          -  postoperative atrial fibrillation requiring anticoagulation

          -  postoperative hemorrhagic events (stroke, GI bleeding)

          -  occurrence of contraindications to acetylsalicylic acid or ticagrelor

          -  surgical treatment requiring DAPT withdrawn

          -  patient decision
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Massimo Chello, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Università Campus Bio-Medico di Roma, Rome, Italy</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Antonio Nenna, MD</last_name>
    <phone>+393337014743</phone>
    <email>a.nenna@unicampus.it</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Massimo Chello, MD</last_name>
    <email>m.chello@unicampus.it</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Università Campus Bio-Medico di Roma</name>
      <address>
        <city>Rome</city>
        <zip>00128</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Nenna, MD</last_name>
      <phone>+393337014743</phone>
      <email>a.nenna@unicampus.it</email>
    </contact>
    <contact_backup>
      <last_name>Massimo Chello, MD</last_name>
      <email>m.chello@unicampus.it</email>
    </contact_backup>
    <investigator>
      <last_name>Antonio Nenna, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Massimo Chello, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <results_reference>
    <citation>Spadaccio C, Nappi F, Nenna A, Beattie G, Chello M, Sutherland FW. Is it time to change how we think about incomplete coronary revascularization? Int J Cardiol. 2016 Dec 1;224:295-298. doi: 10.1016/j.ijcard.2016.09.055. Epub 2016 Sep 18.</citation>
    <PMID>27665400</PMID>
  </results_reference>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>December 27, 2018</study_first_submitted>
  <study_first_submitted_qc>December 28, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">December 31, 2018</study_first_posted>
  <last_update_submitted>July 13, 2020</last_update_submitted>
  <last_update_submitted_qc>July 13, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 14, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Campus Bio-Medico University</investigator_affiliation>
    <investigator_full_name>Antonio Nenna, MD</investigator_full_name>
    <investigator_title>Cardiovascular Surgery</investigator_title>
  </responsible_party>
  <keyword>coronary artery bypass grafting</keyword>
  <keyword>incomplete revascularization</keyword>
  <keyword>coronary artery disease</keyword>
  <keyword>dual antiplatelet therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aspirin</mesh_term>
    <mesh_term>Ticagrelor</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

